Concanavalin A

A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.

Also Known As:

Networked: 2353 relevant articles (63 outcomes, 170 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gao, Bin: 10 articles (01/2015 - 11/2002)
2.	Feng, Dechun: 9 articles (01/2015 - 02/2008)
3.	Sun, Rui: 9 articles (03/2014 - 05/2004)
4.	Tian, Zhigang: 9 articles (03/2014 - 11/2002)
5.	Annabi, Borhane: 8 articles (05/2014 - 01/2002)
6.	Wei, Haiming: 8 articles (03/2014 - 03/2005)
7.	Ilan, Yaron: 7 articles (06/2015 - 03/2003)
8.	Guo, Chuanyong: 7 articles (01/2015 - 01/2013)
9.	Okamoto, T: 7 articles (09/2001 - 04/2000)
10.	Dai, Weiqi: 6 articles (01/2015 - 01/2013)

Related Diseases

1.	Hepatitis 01/01/2013 - "This study was designed to examine the protective effects and mechanisms of Nec-1 in concanavalin A- (ConA-) induced hepatitis in mice. " 09/01/2011 - "Roles of platelets and macrophages in the protective effects of lipopolysaccharide against concanavalin A-induced murine hepatitis." 09/15/2013 - "C57BL/6 mice were fed a diet supplemented with or without 0.3% (wt/vol) UDCA for 4 wk. UDCA improved hepatocyte injury and survival in concanavalin-A (Con-A)-induced hepatitis by suppressing IFN-γ production by liver mononuclear cells (MNC), especially NK and NKT cells. " 01/01/2012 - "Efficacy of adipose tissue-derived mesenchymal stem cells for fulminant hepatitis in mice induced by concanavalin A." 10/01/2009 - "Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice."
2.	Infection 07/01/1981 - "89Sr-treated mice injected with concanavalin A (Con A) 24 h prior to infection with Listeria monocytogenes (LM) could not enhance the clearance of LM from the spleen. " 10/01/2011 - "Furthermore, the expression of EcLECT2 was differentially up-regulated in liver after infection with Staphyloccocus aureus, Vibrio vulnificus, Vibrio parahaemolyticus, Saccharomyces cerevisiae and Singapore grouper iridovirus (SGIV), while the expression was down-regulated after stimulation with Concanavalin A (Con A). " 06/01/2009 - "Moreover, such infection was accompanied by a more profound immune suppression in the former, as evidenced by the extensive loss of T cells, compromised responses to concanavalin A stimulation, and absence of inflammatory infiltrates within the brain. " 08/15/2008 - "To further explore and characterize the PCV2 infection in swine lymphocytes, an in vitro model using concanavalin A (Con A)-stimulated peripheral blood lymphocytes (PBLs) obtained from clinically healthy PCV2-carrier pigs was introduced. " 12/01/2004 - "Proliferation of bursal B cells (purified AvBu1(+) cells) in response to concanavalin A mitogenic stimulation was significantly suppressed by infection at 1 day old with either the classical STC or variant E strains of IBDV. "
3.	Neoplasms (Cancer) 06/01/1993 - "Four days before the start of treatment, cancer patient PBMC stimulated with concanavalin A (con A) produced significantly greater amounts of TNF compared to normal controls. " 06/01/2004 - "beta(2)m(-/-) donor cells pre-activated with concanavalin A were more efficiently eliminated compared to resting cells, as were MHC(-) tumor cells. " 01/01/1989 - "In one series of trials, spleen cells from strains of chickens with differing levels of susceptibility to MD tumors were stimulated with graded doses of Concanavalin A (Con A) or phytohemagglutin (PHA). " 01/01/1987 - "[Light microscopic studies of concanavalin A binding in the choroid plexus epithelium and ependymal cells of the cerebral ventricle and human tumors derived from those tissues]." 03/25/1975 - "These data support and extend the findings concerning the mobility of the concanavalin A binding/agglutinating sites on the surface of normal and virus-transformed cells and suggest further approaches to the study of the membrane alterations in tumor cells."
4.	Melanoma (Melanoma, Malignant) 07/01/1983 - "Peripheral blood mononuclear cells (PBMC) from 11 patients with metastatic melanoma (group II) had a significant decrease in blastogenesis to concanavalin A (Con A) (38.7 +/- 7.7 cpm X 10(3); mean +/- SE) compared to 21 patients who were disease free (70.6 +/- 6.7) or 16 healthy controls (83.6 +/- 10.3). " 02/01/2009 - "The objective of this study was to investigate the antiproliferative activity and apoptosis-inducing mechanism of Concanavalin A (ConA) on human melanoma A375 cells. " 03/15/1987 - "In this study we examined suppressor T-cell activity in nodes at different distances from primary melanoma, using a concanavalin A (Con A) suppressor cell assay. " 02/01/2009 - "Antiproliferative activity and apoptosis-inducing mechanism of Concanavalin A on human melanoma A375 cells." 01/01/1982 - "MAA were partially purified from crude KCl extract of melanoma tissue by affinity column chromatography using AHMS and concanavalin A. "
5.	Lipoid Nephrosis (Glomerulonephritis, Minimal Change) 07/01/1982 - "A group of 37 patients with minimal change nephropathy (MCN) in remission for a mean period of 4.9 years (range 0.25-10) and on no current treatment were found to have a lymphocyte response to the mitogen Concanavalin A which was significantly lower than normal (P less than 0.001). " 01/31/1981 - "Lymphocyte suppressor-cell function was studied by induction with concanavalin A in 31 patients with minimal-change nephropathy (MCN) in remission. " 08/01/1981 - "Concanavalin A-induced suppressor cell activity in lipoid nephrosis." 10/01/1984 - "The response of lymphocytes to Concanavalin A (Con A) was measured in patients with the nephrotic syndrome due to minimal change nephropathy (11 patients), focal glomerulosclerosis (15 patients) and membranous nephropathy (21 patients); autologous serum was not used in these studies. " 06/01/1981 - "Sera from patients with the nephrotic syndrome due to minimal change nephropathy (11 patients), membranous nephropathy (14 patients) and focal glomerulosclerosis (15 patients) inhibited the response of normal lymphocytes to the mitogen Concanavalin A. "

Related Drugs and Biologics

1.	Antigens
2.	Interleukin-2 (IL2)
3.	Interleukin-6 (Interleukin 6)
4.	Mitogens
5.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
6.	Conditioned Culture Media
7.	Thiazolidinediones
8.	baicalein
9.	Immunoglobulin G (IgG)
10.	Cytokines

Related Therapies and Procedures

1.	Oral Administration
2.	Microspheres (Microsphere)
3.	Transplants (Transplant)
4.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
5.	Drug Therapy (Chemotherapy)